| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Primary Health Care | 31 | 2019 | 703 | 3.120 |
Why?
|
| Scleroderma, Systemic | 17 | 2016 | 446 | 1.830 |
Why?
|
| Humans | 219 | 2023 | 68618 | 1.400 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2014 | 88 | 1.270 |
Why?
|
| Female | 143 | 2022 | 38074 | 1.210 |
Why?
|
| Respiratory Tract Infections | 3 | 2012 | 91 | 1.170 |
Why?
|
| Immunoglobulin Gm Allotypes | 6 | 2021 | 103 | 1.140 |
Why?
|
| Hypertension | 15 | 2019 | 1535 | 1.140 |
Why?
|
| Guideline Adherence | 10 | 2014 | 287 | 1.130 |
Why?
|
| Male | 129 | 2022 | 37321 | 1.110 |
Why?
|
| Adult | 93 | 2021 | 21403 | 1.080 |
Why?
|
| Middle Aged | 100 | 2022 | 21147 | 1.070 |
Why?
|
| Solitary Pulmonary Nodule | 6 | 2014 | 77 | 1.020 |
Why?
|
| Mass Screening | 9 | 2019 | 843 | 0.980 |
Why?
|
| Practice Patterns, Physicians' | 10 | 2013 | 504 | 0.980 |
Why?
|
| Lung Neoplasms | 13 | 2018 | 1173 | 0.910 |
Why?
|
| Alzheimer Disease | 9 | 2022 | 565 | 0.890 |
Why?
|
| Adolescent Behavior | 3 | 2018 | 264 | 0.870 |
Why?
|
| Aged | 74 | 2022 | 14862 | 0.870 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 4 | 2011 | 373 | 0.860 |
Why?
|
| Receptors, IgG | 4 | 2021 | 94 | 0.860 |
Why?
|
| Diabetes Mellitus | 10 | 2019 | 694 | 0.850 |
Why?
|
| Electronic Health Records | 5 | 2015 | 374 | 0.850 |
Why?
|
| Anti-Bacterial Agents | 4 | 2015 | 1026 | 0.850 |
Why?
|
| Anesthetics, Local | 2 | 2014 | 83 | 0.820 |
Why?
|
| United States | 40 | 2021 | 7367 | 0.810 |
Why?
|
| Biostatistics | 4 | 2018 | 43 | 0.800 |
Why?
|
| Lupus Erythematosus, Systemic | 7 | 2022 | 756 | 0.800 |
Why?
|
| Cardiovascular Diseases | 12 | 2020 | 940 | 0.800 |
Why?
|
| Quality Indicators, Health Care | 10 | 2015 | 136 | 0.780 |
Why?
|
| Research Design | 7 | 2021 | 729 | 0.750 |
Why?
|
| Blood Pressure | 7 | 2017 | 1451 | 0.750 |
Why?
|
| Drug Utilization | 6 | 2012 | 119 | 0.740 |
Why?
|
| Cytomegalovirus | 3 | 2016 | 63 | 0.730 |
Why?
|
| Alcoholism | 7 | 2023 | 1109 | 0.720 |
Why?
|
| Chronic Disease | 6 | 2013 | 1330 | 0.720 |
Why?
|
| Decision Support Techniques | 4 | 2013 | 191 | 0.710 |
Why?
|
| Health Services Accessibility | 6 | 2013 | 581 | 0.690 |
Why?
|
| Hypercholesterolemia | 4 | 2019 | 86 | 0.680 |
Why?
|
| Linear Models | 12 | 2018 | 521 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 2324 | 0.670 |
Why?
|
| Anemia, Sickle Cell | 7 | 2021 | 364 | 0.650 |
Why?
|
| Bibliometrics | 1 | 2018 | 25 | 0.630 |
Why?
|
| Publications | 1 | 2018 | 17 | 0.630 |
Why?
|
| Deglutition | 4 | 2016 | 221 | 0.630 |
Why?
|
| Clinical Competence | 6 | 2016 | 657 | 0.630 |
Why?
|
| Bullying | 1 | 2018 | 28 | 0.630 |
Why?
|
| Viral Proteins | 2 | 2016 | 150 | 0.600 |
Why?
|
| White Matter | 4 | 2022 | 174 | 0.590 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 370 | 0.590 |
Why?
|
| Colorectal Neoplasms | 4 | 2010 | 561 | 0.580 |
Why?
|
| Alcohol-Related Disorders | 3 | 2013 | 95 | 0.580 |
Why?
|
| Child | 26 | 2022 | 6405 | 0.580 |
Why?
|
| Graft Survival | 2 | 2017 | 465 | 0.580 |
Why?
|
| Asthma | 2 | 2018 | 345 | 0.570 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 39 | 0.570 |
Why?
|
| Internal Medicine | 5 | 2012 | 118 | 0.560 |
Why?
|
| Graft Rejection | 2 | 2017 | 458 | 0.550 |
Why?
|
| Telephone | 3 | 2009 | 160 | 0.550 |
Why?
|
| Reminder Systems | 3 | 2009 | 39 | 0.540 |
Why?
|
| Students | 1 | 2018 | 233 | 0.540 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 6 | 2022 | 239 | 0.540 |
Why?
|
| Voice Disorders | 2 | 2016 | 22 | 0.540 |
Why?
|
| Oxytocin | 5 | 2023 | 124 | 0.540 |
Why?
|
| Alcohol Drinking | 3 | 2018 | 805 | 0.530 |
Why?
|
| Cough | 2 | 2016 | 65 | 0.530 |
Why?
|
| Medication Errors | 3 | 2012 | 116 | 0.530 |
Why?
|
| Antihypertensive Agents | 7 | 2014 | 498 | 0.520 |
Why?
|
| Hepatorenal Syndrome | 2 | 2015 | 16 | 0.520 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 164 | 0.520 |
Why?
|
| Adolescent | 29 | 2019 | 8912 | 0.520 |
Why?
|
| Clinical Protocols | 2 | 2015 | 172 | 0.520 |
Why?
|
| Publishing | 3 | 2017 | 89 | 0.510 |
Why?
|
| Accidental Falls | 2 | 2007 | 84 | 0.510 |
Why?
|
| Inappropriate Prescribing | 2 | 2012 | 27 | 0.510 |
Why?
|
| Weightlessness | 3 | 2020 | 25 | 0.510 |
Why?
|
| Decision Making | 5 | 2019 | 410 | 0.510 |
Why?
|
| Crime Victims | 1 | 2018 | 286 | 0.510 |
Why?
|
| Vasoconstrictor Agents | 2 | 2015 | 107 | 0.500 |
Why?
|
| Probability | 5 | 2021 | 245 | 0.490 |
Why?
|
| Risk Factors | 21 | 2021 | 5731 | 0.490 |
Why?
|
| South Carolina | 20 | 2016 | 2752 | 0.480 |
Why?
|
| Health Services | 3 | 2014 | 87 | 0.480 |
Why?
|
| Advanced Cardiac Life Support | 4 | 2016 | 22 | 0.470 |
Why?
|
| Preoperative Care | 3 | 2015 | 275 | 0.460 |
Why?
|
| Hospital Mortality | 5 | 2013 | 384 | 0.450 |
Why?
|
| Patient Satisfaction | 5 | 2016 | 378 | 0.450 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 514 | 0.440 |
Why?
|
| Retrospective Studies | 27 | 2022 | 7277 | 0.440 |
Why?
|
| Health Status Disparities | 5 | 2019 | 326 | 0.430 |
Why?
|
| Preventive Health Services | 1 | 2013 | 86 | 0.420 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2012 | 16 | 0.420 |
Why?
|
| Acute Coronary Syndrome | 1 | 2014 | 195 | 0.420 |
Why?
|
| Professional Autonomy | 1 | 2012 | 24 | 0.420 |
Why?
|
| Habits | 1 | 2012 | 14 | 0.410 |
Why?
|
| Depression | 5 | 2020 | 943 | 0.410 |
Why?
|
| Educational Measurement | 1 | 2014 | 254 | 0.410 |
Why?
|
| Social Adjustment | 1 | 2012 | 74 | 0.410 |
Why?
|
| Treatment Outcome | 18 | 2018 | 7029 | 0.410 |
Why?
|
| Sensation | 1 | 2012 | 49 | 0.410 |
Why?
|
| Prospective Studies | 18 | 2021 | 3705 | 0.410 |
Why?
|
| Larynx | 1 | 2012 | 49 | 0.400 |
Why?
|
| Health Education | 2 | 2012 | 279 | 0.400 |
Why?
|
| Community-Based Participatory Research | 1 | 2013 | 133 | 0.400 |
Why?
|
| Cohort Studies | 17 | 2022 | 2358 | 0.400 |
Why?
|
| Students, Medical | 1 | 2014 | 210 | 0.400 |
Why?
|
| Mental Disorders | 2 | 2007 | 659 | 0.400 |
Why?
|
| Pharynx | 1 | 2012 | 89 | 0.390 |
Why?
|
| Quality Improvement | 2 | 2013 | 413 | 0.390 |
Why?
|
| Hospitalization | 8 | 2013 | 978 | 0.390 |
Why?
|
| Cross-Sectional Studies | 14 | 2021 | 2279 | 0.380 |
Why?
|
| Shoulder Pain | 1 | 2011 | 12 | 0.380 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2011 | 26 | 0.380 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2022 | 40 | 0.380 |
Why?
|
| Interview, Psychological | 3 | 2007 | 113 | 0.380 |
Why?
|
| Child, Preschool | 15 | 2022 | 3187 | 0.380 |
Why?
|
| Time Factors | 12 | 2021 | 4655 | 0.380 |
Why?
|
| Bupivacaine | 1 | 2011 | 27 | 0.380 |
Why?
|
| Quality of Life | 7 | 2019 | 1515 | 0.370 |
Why?
|
| Genotype | 8 | 2021 | 786 | 0.370 |
Why?
|
| Uncertainty | 1 | 2010 | 31 | 0.370 |
Why?
|
| Amides | 1 | 2011 | 86 | 0.370 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.370 |
Why?
|
| Tonsillectomy | 2 | 2022 | 69 | 0.360 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2010 | 30 | 0.360 |
Why?
|
| Nerve Block | 1 | 2011 | 55 | 0.360 |
Why?
|
| Caregivers | 4 | 2015 | 365 | 0.360 |
Why?
|
| Hospital Charges | 2 | 2001 | 60 | 0.360 |
Why?
|
| Solvents | 3 | 2001 | 109 | 0.360 |
Why?
|
| Arthroscopy | 1 | 2011 | 95 | 0.360 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 792 | 0.360 |
Why?
|
| Cytomegalovirus Infections | 3 | 2016 | 69 | 0.350 |
Why?
|
| Curriculum | 1 | 2014 | 575 | 0.350 |
Why?
|
| Software | 3 | 2013 | 418 | 0.350 |
Why?
|
| Brain | 8 | 2022 | 2176 | 0.350 |
Why?
|
| Health Status | 4 | 2007 | 429 | 0.350 |
Why?
|
| Veterans | 4 | 2023 | 904 | 0.350 |
Why?
|
| Spinal Cord Injuries | 2 | 2007 | 551 | 0.350 |
Why?
|
| Risk Assessment | 9 | 2021 | 2007 | 0.340 |
Why?
|
| Models, Statistical | 3 | 2014 | 448 | 0.340 |
Why?
|
| Heart Arrest | 3 | 2016 | 113 | 0.340 |
Why?
|
| Length of Stay | 5 | 2019 | 780 | 0.340 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2022 | 63 | 0.340 |
Why?
|
| Shoulder Joint | 1 | 2011 | 110 | 0.340 |
Why?
|
| Colonoscopy | 1 | 2010 | 156 | 0.340 |
Why?
|
| Physicians | 3 | 2017 | 324 | 0.330 |
Why?
|
| Telefacsimile | 1 | 2009 | 6 | 0.330 |
Why?
|
| Pleural Effusion | 3 | 2016 | 74 | 0.330 |
Why?
|
| Divorce | 1 | 2008 | 5 | 0.330 |
Why?
|
| Pharmacies | 1 | 2009 | 18 | 0.330 |
Why?
|
| Pain, Postoperative | 1 | 2011 | 214 | 0.330 |
Why?
|
| Infant | 12 | 2017 | 2891 | 0.320 |
Why?
|
| Substance-Related Disorders | 3 | 2020 | 1242 | 0.320 |
Why?
|
| Smoking | 5 | 2006 | 1452 | 0.320 |
Why?
|
| Markov Chains | 5 | 2008 | 133 | 0.320 |
Why?
|
| Logistic Models | 9 | 2017 | 1420 | 0.320 |
Why?
|
| Couples Therapy | 2 | 2019 | 10 | 0.320 |
Why?
|
| Vascular Diseases | 2 | 2010 | 94 | 0.320 |
Why?
|
| Diet | 2 | 2002 | 514 | 0.310 |
Why?
|
| Demography | 3 | 2005 | 279 | 0.310 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 848 | 0.310 |
Why?
|
| Pediatric Emergency Medicine | 2 | 2019 | 14 | 0.310 |
Why?
|
| Aged, 80 and over | 23 | 2022 | 4848 | 0.310 |
Why?
|
| Double-Blind Method | 6 | 2022 | 1738 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 1536 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 931 | 0.300 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2019 | 101 | 0.300 |
Why?
|
| Emergency Service, Hospital | 4 | 2019 | 711 | 0.300 |
Why?
|
| Sensitivity and Specificity | 9 | 2021 | 1753 | 0.290 |
Why?
|
| Sphingolipids | 2 | 2021 | 337 | 0.290 |
Why?
|
| Computer Simulation | 5 | 2022 | 706 | 0.290 |
Why?
|
| Cerebellar Nuclei | 2 | 2018 | 11 | 0.290 |
Why?
|
| Lactones | 2 | 2006 | 64 | 0.290 |
Why?
|
| Pilot Projects | 9 | 2017 | 1342 | 0.290 |
Why?
|
| Psychotherapy, Group | 1 | 2007 | 55 | 0.290 |
Why?
|
| Medicaid | 2 | 2009 | 302 | 0.280 |
Why?
|
| User-Computer Interface | 2 | 2012 | 230 | 0.280 |
Why?
|
| Antipsychotic Agents | 2 | 2008 | 247 | 0.280 |
Why?
|
| Young Adult | 16 | 2021 | 5717 | 0.280 |
Why?
|
| Sulfonamides | 2 | 2006 | 141 | 0.280 |
Why?
|
| Joint Deformities, Acquired | 1 | 2006 | 5 | 0.270 |
Why?
|
| Patients | 2 | 2005 | 69 | 0.270 |
Why?
|
| Blood Pressure Determination | 4 | 2017 | 152 | 0.270 |
Why?
|
| Propensity Score | 4 | 2021 | 117 | 0.270 |
Why?
|
| Surveys and Questionnaires | 14 | 2021 | 2800 | 0.270 |
Why?
|
| Pre-Eclampsia | 2 | 2020 | 202 | 0.260 |
Why?
|
| Cost of Illness | 1 | 2007 | 206 | 0.260 |
Why?
|
| Knee Joint | 1 | 2006 | 115 | 0.260 |
Why?
|
| Dental Health Services | 1 | 2005 | 11 | 0.260 |
Why?
|
| Tibia | 1 | 2006 | 93 | 0.260 |
Why?
|
| Risperidone | 1 | 2005 | 48 | 0.260 |
Why?
|
| Cognition | 5 | 2020 | 513 | 0.250 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.250 |
Why?
|
| Quality of Health Care | 4 | 2013 | 322 | 0.250 |
Why?
|
| Vitamin D | 2 | 2020 | 516 | 0.250 |
Why?
|
| Hydrocortisone | 2 | 2017 | 291 | 0.250 |
Why?
|
| Follow-Up Studies | 9 | 2017 | 3259 | 0.250 |
Why?
|
| Comorbidity | 8 | 2019 | 1426 | 0.250 |
Why?
|
| Mental Health Services | 1 | 2007 | 199 | 0.250 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2005 | 47 | 0.250 |
Why?
|
| Algorithms | 6 | 2021 | 1196 | 0.250 |
Why?
|
| Health Care Reform | 1 | 2005 | 62 | 0.250 |
Why?
|
| Health Expenditures | 1 | 2007 | 170 | 0.250 |
Why?
|
| Bronchoscopy | 3 | 2018 | 147 | 0.250 |
Why?
|
| Health Services Research | 3 | 2013 | 209 | 0.250 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 107 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 6 | 2014 | 772 | 0.250 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 208 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 8 | 2015 | 177 | 0.240 |
Why?
|
| Spatial Analysis | 3 | 2021 | 33 | 0.240 |
Why?
|
| Ambulatory Care | 2 | 2022 | 340 | 0.230 |
Why?
|
| Stroke | 7 | 2020 | 2163 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 107 | 0.230 |
Why?
|
| Bias | 3 | 2021 | 148 | 0.230 |
Why?
|
| Pneumonia | 2 | 2016 | 110 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 536 | 0.230 |
Why?
|
| Immunoglobulin G | 5 | 2022 | 481 | 0.230 |
Why?
|
| Occupational Exposure | 3 | 2000 | 122 | 0.230 |
Why?
|
| Blood Transfusion | 2 | 2008 | 205 | 0.230 |
Why?
|
| Hypertension, Pulmonary | 3 | 2014 | 232 | 0.230 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 567 | 0.230 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2022 | 211 | 0.230 |
Why?
|
| Motivation | 1 | 2007 | 561 | 0.220 |
Why?
|
| Multivariate Analysis | 8 | 2018 | 1046 | 0.220 |
Why?
|
| Child Health Services | 1 | 2004 | 50 | 0.220 |
Why?
|
| Office Visits | 3 | 2013 | 83 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2006 | 434 | 0.220 |
Why?
|
| Religion and Medicine | 1 | 2003 | 25 | 0.220 |
Why?
|
| Patient Simulation | 2 | 2014 | 64 | 0.220 |
Why?
|
| Confidence Intervals | 3 | 2010 | 242 | 0.220 |
Why?
|
| Esophagoscopy | 1 | 2003 | 72 | 0.220 |
Why?
|
| Vascular Surgical Procedures | 1 | 2004 | 168 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 468 | 0.220 |
Why?
|
| Kidney Diseases | 3 | 2011 | 307 | 0.210 |
Why?
|
| Voice | 1 | 2003 | 16 | 0.210 |
Why?
|
| Checklist | 2 | 2014 | 76 | 0.210 |
Why?
|
| Incidence | 7 | 2021 | 1603 | 0.210 |
Why?
|
| Depressive Disorder | 2 | 2006 | 621 | 0.210 |
Why?
|
| Urban Population | 1 | 2004 | 255 | 0.210 |
Why?
|
| Heart Transplantation | 2 | 2017 | 328 | 0.210 |
Why?
|
| Age Factors | 8 | 2017 | 1864 | 0.210 |
Why?
|
| Barrett Esophagus | 1 | 2003 | 57 | 0.210 |
Why?
|
| Risk-Taking | 2 | 2018 | 210 | 0.210 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 426 | 0.210 |
Why?
|
| Urine | 2 | 2013 | 47 | 0.210 |
Why?
|
| Drug Prescriptions | 4 | 2012 | 135 | 0.210 |
Why?
|
| Odds Ratio | 6 | 2010 | 880 | 0.210 |
Why?
|
| Heart Failure | 3 | 2018 | 1180 | 0.210 |
Why?
|
| Exudates and Transudates | 2 | 2013 | 25 | 0.210 |
Why?
|
| Continuity of Patient Care | 1 | 2004 | 170 | 0.200 |
Why?
|
| Milk | 1 | 2002 | 43 | 0.200 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2002 | 4 | 0.200 |
Why?
|
| Causality | 1 | 2022 | 82 | 0.200 |
Why?
|
| Smoking Prevention | 2 | 2003 | 259 | 0.200 |
Why?
|
| Hospitals, University | 5 | 2010 | 169 | 0.200 |
Why?
|
| Patient Education as Topic | 3 | 2007 | 425 | 0.200 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 150 | 0.200 |
Why?
|
| Reproducibility of Results | 9 | 2018 | 2077 | 0.200 |
Why?
|
| Infant, Newborn | 8 | 2015 | 2455 | 0.200 |
Why?
|
| Academic Medical Centers | 3 | 2013 | 281 | 0.200 |
Why?
|
| Nephrologists | 1 | 2021 | 7 | 0.200 |
Why?
|
| Fruit | 1 | 2002 | 86 | 0.200 |
Why?
|
| Vegetables | 1 | 2002 | 76 | 0.200 |
Why?
|
| Phantoms, Imaging | 3 | 2013 | 189 | 0.200 |
Why?
|
| Pediatricians | 1 | 2021 | 9 | 0.200 |
Why?
|
| Internship and Residency | 3 | 2017 | 596 | 0.200 |
Why?
|
| Rheumatologists | 1 | 2021 | 14 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 475 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2014 | 110 | 0.190 |
Why?
|
| Hospitals, Community | 1 | 2001 | 64 | 0.190 |
Why?
|
| Attitude of Health Personnel | 6 | 2021 | 442 | 0.190 |
Why?
|
| Remission Induction | 1 | 2021 | 111 | 0.190 |
Why?
|
| Medical Records Systems, Computerized | 6 | 2008 | 130 | 0.190 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2023 | 1506 | 0.190 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 216 | 0.190 |
Why?
|
| Immunoglobulin Km Allotypes | 1 | 2021 | 34 | 0.190 |
Why?
|
| Patient-Centered Care | 2 | 2013 | 106 | 0.190 |
Why?
|
| Basal Forebrain | 1 | 2021 | 15 | 0.190 |
Why?
|
| Rituximab | 1 | 2021 | 61 | 0.190 |
Why?
|
| Eating | 1 | 2002 | 119 | 0.190 |
Why?
|
| Case-Control Studies | 6 | 2021 | 1553 | 0.190 |
Why?
|
| Counseling | 2 | 2017 | 280 | 0.190 |
Why?
|
| Ultrasonography | 3 | 2021 | 453 | 0.190 |
Why?
|
| Parents | 1 | 2004 | 312 | 0.190 |
Why?
|
| Rural Population | 1 | 2004 | 398 | 0.190 |
Why?
|
| Antibody Affinity | 3 | 2016 | 26 | 0.180 |
Why?
|
| Carotid Artery Diseases | 1 | 2021 | 83 | 0.180 |
Why?
|
| Acute Disease | 2 | 2012 | 658 | 0.180 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 83 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 72 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2020 | 24 | 0.180 |
Why?
|
| Socioeconomic Factors | 7 | 2011 | 955 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2003 | 318 | 0.180 |
Why?
|
| Pediatrics | 1 | 2004 | 341 | 0.180 |
Why?
|
| Mortality | 3 | 2015 | 163 | 0.180 |
Why?
|
| Family Practice | 4 | 2007 | 312 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2014 | 356 | 0.180 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 110 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2003 | 402 | 0.180 |
Why?
|
| Age Distribution | 4 | 2013 | 320 | 0.180 |
Why?
|
| Hobbies | 1 | 1999 | 4 | 0.180 |
Why?
|
| Tooth Injuries | 1 | 2019 | 3 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2016 | 786 | 0.170 |
Why?
|
| Fees, Medical | 1 | 1999 | 9 | 0.170 |
Why?
|
| Disease Management | 3 | 2014 | 248 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2019 | 33 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 119 | 0.170 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 193 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 149 | 0.170 |
Why?
|
| Marijuana Use | 1 | 2020 | 35 | 0.170 |
Why?
|
| Prevalence | 8 | 2019 | 1619 | 0.170 |
Why?
|
| Reimbursement Mechanisms | 1 | 1999 | 37 | 0.170 |
Why?
|
| Astronauts | 1 | 2019 | 20 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 58 | 0.170 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2012 | 63 | 0.170 |
Why?
|
| Oxytocics | 1 | 2019 | 14 | 0.170 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 546 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 214 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2017 | 150 | 0.170 |
Why?
|
| Pituitary-Adrenal System | 2 | 2017 | 138 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 1851 | 0.170 |
Why?
|
| Educational Status | 4 | 2005 | 273 | 0.160 |
Why?
|
| Exercise | 3 | 2017 | 658 | 0.160 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 1465 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2007 | 767 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 253 | 0.160 |
Why?
|
| Protein Binding | 4 | 2016 | 1027 | 0.160 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 142 | 0.160 |
Why?
|
| Space Flight | 1 | 2019 | 40 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 108 | 0.160 |
Why?
|
| Biomarkers | 8 | 2022 | 1593 | 0.160 |
Why?
|
| Benchmarking | 3 | 2008 | 91 | 0.160 |
Why?
|
| Mucin-1 | 2 | 2009 | 35 | 0.160 |
Why?
|
| Insurance, Health | 2 | 2014 | 201 | 0.160 |
Why?
|
| Health Plan Implementation | 2 | 2010 | 37 | 0.160 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 215 | 0.160 |
Why?
|
| Risk | 4 | 2014 | 563 | 0.160 |
Why?
|
| Vascular Stiffness | 1 | 2018 | 31 | 0.160 |
Why?
|
| Prenatal Care | 1 | 2019 | 117 | 0.160 |
Why?
|
| Placenta | 2 | 2020 | 101 | 0.160 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2018 | 6 | 0.160 |
Why?
|
| Databases, Factual | 3 | 2017 | 622 | 0.160 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2018 | 7 | 0.160 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 81 | 0.150 |
Why?
|
| Myocardium | 2 | 2015 | 1204 | 0.150 |
Why?
|
| Craving | 2 | 2022 | 200 | 0.150 |
Why?
|
| Hyponatremia | 1 | 2018 | 20 | 0.150 |
Why?
|
| Meglumine | 1 | 2018 | 16 | 0.150 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 208 | 0.150 |
Why?
|
| Family Conflict | 1 | 2017 | 6 | 0.150 |
Why?
|
| Pancreatitis | 2 | 2017 | 279 | 0.150 |
Why?
|
| Viral Core Proteins | 2 | 2008 | 12 | 0.150 |
Why?
|
| Negotiating | 1 | 2017 | 18 | 0.150 |
Why?
|
| Pancreatitis, Chronic | 1 | 2019 | 168 | 0.150 |
Why?
|
| Lung | 3 | 2014 | 849 | 0.150 |
Why?
|
| Sex Distribution | 3 | 2003 | 274 | 0.150 |
Why?
|
| Organic Chemicals | 1 | 1998 | 77 | 0.150 |
Why?
|
| Administration, Oral | 3 | 2019 | 411 | 0.150 |
Why?
|
| Globus Pallidus | 1 | 2018 | 64 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 161 | 0.150 |
Why?
|
| Health Surveys | 4 | 2007 | 489 | 0.150 |
Why?
|
| Creatinine | 3 | 2015 | 243 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 283 | 0.150 |
Why?
|
| Psychomotor Agitation | 3 | 2008 | 63 | 0.150 |
Why?
|
| Fluoroscopy | 1 | 2018 | 152 | 0.150 |
Why?
|
| Anesthesiology | 2 | 2016 | 63 | 0.150 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 106 | 0.140 |
Why?
|
| Immunoglobulins | 1 | 2017 | 97 | 0.140 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2007 | 151 | 0.140 |
Why?
|
| Public Health | 1 | 2019 | 201 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 95 | 0.140 |
Why?
|
| Movement Disorders | 1 | 2017 | 58 | 0.140 |
Why?
|
| Cause of Death | 2 | 2008 | 241 | 0.140 |
Why?
|
| Television | 2 | 2006 | 28 | 0.140 |
Why?
|
| Marijuana Abuse | 1 | 2020 | 251 | 0.140 |
Why?
|
| Animals | 10 | 2022 | 20881 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 2223 | 0.140 |
Why?
|
| Life Expectancy | 2 | 2015 | 51 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 157 | 0.140 |
Why?
|
| Behavior Therapy | 1 | 2019 | 297 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 700 | 0.140 |
Why?
|
| Contrast Media | 2 | 2018 | 595 | 0.140 |
Why?
|
| Mucus | 1 | 2016 | 33 | 0.140 |
Why?
|
| Vocal Cords | 1 | 2016 | 18 | 0.140 |
Why?
|
| Drinking | 1 | 2016 | 35 | 0.140 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 301 | 0.140 |
Why?
|
| Life Style | 2 | 2017 | 338 | 0.140 |
Why?
|
| Object Attachment | 1 | 2016 | 20 | 0.140 |
Why?
|
| Gadolinium DTPA | 1 | 2016 | 48 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 3 | 2017 | 329 | 0.140 |
Why?
|
| Voice Quality | 1 | 2016 | 21 | 0.140 |
Why?
|
| Diffusion of Innovation | 2 | 2007 | 102 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 84 | 0.130 |
Why?
|
| Cholesterol | 1 | 2017 | 331 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 507 | 0.130 |
Why?
|
| Mother-Child Relations | 1 | 2016 | 43 | 0.130 |
Why?
|
| Schizophrenia | 1 | 2017 | 206 | 0.130 |
Why?
|
| Mediastinum | 2 | 2014 | 39 | 0.130 |
Why?
|
| Neoplasms | 2 | 2006 | 1667 | 0.130 |
Why?
|
| Medical Audit | 4 | 2008 | 44 | 0.130 |
Why?
|
| Arterial Pressure | 1 | 2015 | 47 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 378 | 0.130 |
Why?
|
| Random Allocation | 4 | 2021 | 442 | 0.130 |
Why?
|
| Stress, Psychological | 3 | 2017 | 824 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 800 | 0.130 |
Why?
|
| Ceramides | 1 | 2019 | 578 | 0.130 |
Why?
|
| Lactulose | 1 | 2015 | 13 | 0.130 |
Why?
|
| Mannitol | 1 | 2015 | 25 | 0.130 |
Why?
|
| Infant Formula | 1 | 2015 | 24 | 0.130 |
Why?
|
| Sulfones | 2 | 2006 | 45 | 0.130 |
Why?
|
| Meaningful Use | 1 | 2015 | 21 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2015 | 59 | 0.120 |
Why?
|
| Connectin | 1 | 2015 | 14 | 0.120 |
Why?
|
| Acute Kidney Injury | 2 | 2015 | 232 | 0.120 |
Why?
|
| Cycloserine | 1 | 2015 | 30 | 0.120 |
Why?
|
| Antibody Formation | 2 | 2021 | 93 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2017 | 310 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2015 | 115 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2010 | 454 | 0.120 |
Why?
|
| Manometry | 2 | 2013 | 276 | 0.120 |
Why?
|
| Perception | 1 | 2016 | 189 | 0.120 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 8 | 0.120 |
Why?
|
| HLA-DQ Antigens | 1 | 2014 | 19 | 0.120 |
Why?
|
| Mothers | 1 | 2016 | 172 | 0.120 |
Why?
|
| Pericardium | 1 | 2015 | 97 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2014 | 52 | 0.120 |
Why?
|
| Tobacco Industry | 1 | 2014 | 55 | 0.120 |
Why?
|
| Community Health Services | 1 | 2015 | 141 | 0.120 |
Why?
|
| Bronchi | 1 | 2014 | 59 | 0.120 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 38 | 0.120 |
Why?
|
| Triage | 1 | 2015 | 109 | 0.120 |
Why?
|
| Chorion | 1 | 2014 | 13 | 0.120 |
Why?
|
| Pregnancy, Twin | 1 | 2014 | 9 | 0.120 |
Why?
|
| Esophagus | 2 | 2013 | 303 | 0.120 |
Why?
|
| Trichloroethylene | 2 | 2009 | 41 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2015 | 291 | 0.120 |
Why?
|
| Stillbirth | 1 | 2014 | 12 | 0.120 |
Why?
|
| Child Abuse, Sexual | 1 | 2015 | 150 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 219 | 0.120 |
Why?
|
| Fetal Death | 1 | 2014 | 49 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 1745 | 0.120 |
Why?
|
| Sample Size | 2 | 2011 | 79 | 0.120 |
Why?
|
| Sex Factors | 4 | 2017 | 1266 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2006 | 190 | 0.110 |
Why?
|
| Immunity, Humoral | 2 | 2012 | 42 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2015 | 221 | 0.110 |
Why?
|
| Perioperative Care | 1 | 2014 | 100 | 0.110 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2013 | 18 | 0.110 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 306 | 0.110 |
Why?
|
| Observer Variation | 2 | 2013 | 330 | 0.110 |
Why?
|
| Vascular Calcification | 1 | 2015 | 131 | 0.110 |
Why?
|
| Mice, Transgenic | 3 | 2022 | 1033 | 0.110 |
Why?
|
| Telemedicine | 1 | 2022 | 700 | 0.110 |
Why?
|
| Milk, Human | 1 | 2015 | 147 | 0.110 |
Why?
|
| Albuminuria | 2 | 2011 | 171 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 742 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 66 | 0.110 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 20 | 0.110 |
Why?
|
| Warfarin | 1 | 2014 | 93 | 0.110 |
Why?
|
| Psychotherapy, Brief | 1 | 2013 | 30 | 0.110 |
Why?
|
| Inflammasomes | 1 | 2013 | 39 | 0.110 |
Why?
|
| Personnel Management | 1 | 2013 | 11 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 38 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2014 | 195 | 0.110 |
Why?
|
| Glycosphingolipids | 1 | 2013 | 51 | 0.110 |
Why?
|
| Iodine | 1 | 2013 | 42 | 0.110 |
Why?
|
| Prognosis | 5 | 2021 | 2093 | 0.110 |
Why?
|
| Qualitative Research | 2 | 2012 | 369 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2013 | 108 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2014 | 258 | 0.110 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 66 | 0.110 |
Why?
|
| Data Collection | 2 | 2012 | 420 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 144 | 0.110 |
Why?
|
| Bronchitis | 1 | 2012 | 8 | 0.110 |
Why?
|
| Implosive Therapy | 1 | 2015 | 171 | 0.110 |
Why?
|
| Alcohol Deterrents | 1 | 2013 | 86 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2013 | 82 | 0.110 |
Why?
|
| Infant, Premature, Diseases | 1 | 2014 | 85 | 0.110 |
Why?
|
| Gestational Age | 1 | 2014 | 389 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 72 | 0.110 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2013 | 92 | 0.110 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2013 | 106 | 0.110 |
Why?
|
| Models, Organizational | 3 | 2009 | 97 | 0.110 |
Why?
|
| Catheterization | 1 | 2013 | 209 | 0.110 |
Why?
|
| Partnership Practice | 1 | 2012 | 4 | 0.110 |
Why?
|
| Drug Incompatibility | 1 | 2012 | 7 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 3 | 2008 | 504 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 248 | 0.100 |
Why?
|
| Sepsis | 1 | 2015 | 233 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2015 | 450 | 0.100 |
Why?
|
| Systems Integration | 1 | 2012 | 30 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2007 | 902 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 138 | 0.100 |
Why?
|
| Aging | 1 | 2018 | 911 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1085 | 0.100 |
Why?
|
| Esophageal Spasm, Diffuse | 1 | 2012 | 13 | 0.100 |
Why?
|
| Gastrointestinal Transit | 1 | 2012 | 16 | 0.100 |
Why?
|
| Biometry | 1 | 2012 | 72 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 52 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2012 | 71 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 225 | 0.100 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 301 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 649 | 0.100 |
Why?
|
| Certification | 1 | 2012 | 66 | 0.100 |
Why?
|
| Tobacco Products | 1 | 2014 | 234 | 0.100 |
Why?
|
| Collagen | 1 | 2015 | 636 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 104 | 0.100 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 323 | 0.100 |
Why?
|
| Treatment Refusal | 2 | 2008 | 40 | 0.100 |
Why?
|
| Video Recording | 1 | 2012 | 145 | 0.100 |
Why?
|
| Vaccines | 1 | 2011 | 21 | 0.100 |
Why?
|
| Renin | 1 | 2011 | 96 | 0.100 |
Why?
|
| Cell Line | 1 | 2015 | 1752 | 0.100 |
Why?
|
| Pregnancy | 4 | 2020 | 2334 | 0.100 |
Why?
|
| Brachial Plexus | 1 | 2011 | 15 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2012 | 79 | 0.100 |
Why?
|
| Oxycodone | 1 | 2011 | 10 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2017 | 665 | 0.100 |
Why?
|
| Coronary Disease | 2 | 2020 | 358 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2011 | 20 | 0.100 |
Why?
|
| Hydrothorax | 1 | 2011 | 7 | 0.090 |
Why?
|
| Program Development | 1 | 2012 | 240 | 0.090 |
Why?
|
| Antithrombins | 1 | 2011 | 32 | 0.090 |
Why?
|
| Age of Onset | 2 | 2014 | 188 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 157 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2019 | 260 | 0.090 |
Why?
|
| Injections | 1 | 2011 | 119 | 0.090 |
Why?
|
| Binomial Distribution | 1 | 2010 | 4 | 0.090 |
Why?
|
| Ascites | 1 | 2011 | 38 | 0.090 |
Why?
|
| Echocardiography | 2 | 2011 | 515 | 0.090 |
Why?
|
| Estonia | 1 | 2010 | 3 | 0.090 |
Why?
|
| Costs and Cost Analysis | 2 | 2003 | 193 | 0.090 |
Why?
|
| Nephrectomy | 1 | 2011 | 103 | 0.090 |
Why?
|
| Mice | 6 | 2022 | 8474 | 0.090 |
Why?
|
| Thrombin | 1 | 2011 | 117 | 0.090 |
Why?
|
| Cues | 1 | 2015 | 654 | 0.090 |
Why?
|
| Immediate-Early Proteins | 2 | 2007 | 63 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 148 | 0.090 |
Why?
|
| Nursing Staff | 2 | 2007 | 30 | 0.090 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2010 | 5 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 446 | 0.090 |
Why?
|
| Disease Progression | 4 | 2018 | 1038 | 0.090 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 348 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 100 | 0.090 |
Why?
|
| Autoimmune Diseases | 2 | 2009 | 186 | 0.090 |
Why?
|
| Acetaminophen | 1 | 2011 | 111 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 103 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2011 | 163 | 0.090 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.090 |
Why?
|
| beta-Thalassemia | 1 | 2010 | 17 | 0.090 |
Why?
|
| Artifacts | 2 | 2013 | 125 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 239 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2011 | 128 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 2 | 2003 | 296 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 163 | 0.090 |
Why?
|
| Administration, Intranasal | 2 | 2022 | 88 | 0.090 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2000 | 7 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2012 | 328 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2014 | 753 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 365 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2011 | 328 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2008 | 90 | 0.090 |
Why?
|
| Body Fluids | 2 | 2000 | 41 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2007 | 146 | 0.090 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 504 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 807 | 0.090 |
Why?
|
| Analgesics | 1 | 2011 | 118 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 212 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 129 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 2550 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 597 | 0.090 |
Why?
|
| Regression Analysis | 4 | 2014 | 737 | 0.080 |
Why?
|
| Health Care Surveys | 2 | 2015 | 239 | 0.080 |
Why?
|
| Survival Rate | 3 | 2013 | 1056 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 2011 | 157 | 0.080 |
Why?
|
| Total Quality Management | 2 | 2007 | 45 | 0.080 |
Why?
|
| Drug Utilization Review | 2 | 2006 | 19 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 297 | 0.080 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2009 | 8 | 0.080 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 12 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 109 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 696 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 951 | 0.080 |
Why?
|
| Pain | 1 | 2012 | 472 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2004 | 346 | 0.080 |
Why?
|
| Terminally Ill | 1 | 2008 | 17 | 0.080 |
Why?
|
| Directive Counseling | 1 | 2009 | 23 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 300 | 0.080 |
Why?
|
| Heart | 1 | 2013 | 850 | 0.080 |
Why?
|
| Immune System | 1 | 2009 | 63 | 0.080 |
Why?
|
| Hospice Care | 1 | 2008 | 29 | 0.080 |
Why?
|
| Anisotropy | 2 | 2020 | 105 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 765 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 70 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 329 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2009 | 132 | 0.080 |
Why?
|
| Respiration, Artificial | 2 | 2013 | 190 | 0.080 |
Why?
|
| Personality | 1 | 2008 | 66 | 0.080 |
Why?
|
| Hepatitis C Antibodies | 1 | 2008 | 19 | 0.080 |
Why?
|
| Alleles | 2 | 2021 | 386 | 0.080 |
Why?
|
| Immunoglobulin Allotypes | 1 | 2008 | 82 | 0.080 |
Why?
|
| Islets of Langerhans | 2 | 2019 | 87 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2017 | 867 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2008 | 219 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2011 | 506 | 0.080 |
Why?
|
| Ferritins | 1 | 2008 | 49 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2008 | 64 | 0.080 |
Why?
|
| Celecoxib | 2 | 2006 | 22 | 0.080 |
Why?
|
| Pancreatectomy | 2 | 2019 | 129 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1054 | 0.070 |
Why?
|
| Peroxidase | 1 | 2007 | 40 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2015 | 249 | 0.070 |
Why?
|
| Extinction, Psychological | 2 | 2023 | 240 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 48 | 0.070 |
Why?
|
| Nursing Research | 1 | 2007 | 40 | 0.070 |
Why?
|
| Obesity | 1 | 2014 | 1076 | 0.070 |
Why?
|
| Practice Management, Medical | 1 | 2007 | 24 | 0.070 |
Why?
|
| Dependent Ambulation | 1 | 2007 | 6 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2008 | 106 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2008 | 130 | 0.070 |
Why?
|
| Sinusitis | 1 | 2012 | 432 | 0.070 |
Why?
|
| Physician-Patient Relations | 2 | 2006 | 261 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2007 | 98 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2007 | 175 | 0.070 |
Why?
|
| Axons | 2 | 2018 | 139 | 0.070 |
Why?
|
| Aftercare | 1 | 2007 | 114 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2009 | 502 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2008 | 157 | 0.070 |
Why?
|
| Southeastern United States | 1 | 2007 | 281 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 46 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2006 | 403 | 0.070 |
Why?
|
| Kidney | 1 | 2011 | 945 | 0.070 |
Why?
|
| Postal Service | 1 | 2006 | 19 | 0.070 |
Why?
|
| Rotation | 1 | 2006 | 58 | 0.070 |
Why?
|
| Drug Industry | 1 | 2006 | 54 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 756 | 0.070 |
Why?
|
| Environmental Exposure | 3 | 2009 | 269 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 161 | 0.070 |
Why?
|
| Clothing | 1 | 2005 | 7 | 0.070 |
Why?
|
| Osteoarthritis | 1 | 2006 | 73 | 0.070 |
Why?
|
| Iron | 1 | 2008 | 197 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 298 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 2005 | 31 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2013 | 618 | 0.060 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 139 | 0.060 |
Why?
|
| Insulin | 2 | 2019 | 619 | 0.060 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2006 | 204 | 0.060 |
Why?
|
| Placebos | 1 | 2005 | 195 | 0.060 |
Why?
|
| Gene Expression | 2 | 2020 | 770 | 0.060 |
Why?
|
| Trust | 1 | 2005 | 75 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2013 | 67 | 0.060 |
Why?
|
| Health Promotion | 1 | 2009 | 407 | 0.060 |
Why?
|
| Dementia | 2 | 1998 | 158 | 0.060 |
Why?
|
| Pulmonary Medicine | 1 | 2005 | 31 | 0.060 |
Why?
|
| Critical Care | 2 | 2005 | 263 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2021 | 384 | 0.060 |
Why?
|
| Radiography, Thoracic | 2 | 2016 | 99 | 0.060 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 328 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 627 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 74 | 0.060 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 2004 | 2 | 0.060 |
Why?
|
| Acantholysis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2004 | 108 | 0.060 |
Why?
|
| Keratosis | 1 | 2004 | 17 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 127 | 0.060 |
Why?
|
| Melanocytes | 1 | 2004 | 23 | 0.060 |
Why?
|
| Aggression | 2 | 2022 | 98 | 0.060 |
Why?
|
| Physicians, Family | 1 | 2004 | 83 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2006 | 252 | 0.060 |
Why?
|
| Nevus, Pigmented | 1 | 2004 | 30 | 0.060 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 203 | 0.060 |
Why?
|
| Arteries | 1 | 2004 | 108 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2004 | 45 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2003 | 172 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 2004 | 99 | 0.060 |
Why?
|
| Antibodies | 2 | 2009 | 241 | 0.060 |
Why?
|
| Angioplasty | 1 | 2004 | 118 | 0.060 |
Why?
|
| Motor Activity | 1 | 2007 | 621 | 0.060 |
Why?
|
| Esophagoscopes | 1 | 2003 | 5 | 0.060 |
Why?
|
| Pleurodesis | 2 | 2000 | 11 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 839 | 0.050 |
Why?
|
| Leg | 1 | 2004 | 191 | 0.050 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 209 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 257 | 0.050 |
Why?
|
| Public Health Informatics | 1 | 2003 | 7 | 0.050 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2003 | 13 | 0.050 |
Why?
|
| Smoking Cessation | 2 | 2003 | 1034 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 782 | 0.050 |
Why?
|
| Terminal Care | 1 | 2004 | 92 | 0.050 |
Why?
|
| Organizational Case Studies | 3 | 2009 | 53 | 0.050 |
Why?
|
| Equidae | 1 | 2022 | 3 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2022 | 19 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2003 | 82 | 0.050 |
Why?
|
| SEER Program | 1 | 2003 | 153 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2002 | 24 | 0.050 |
Why?
|
| Liver | 1 | 2008 | 1118 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 41 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2013 | 238 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2021 | 31 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 62 | 0.050 |
Why?
|
| Low Back Pain | 1 | 2002 | 45 | 0.050 |
Why?
|
| Polysomnography | 1 | 2022 | 92 | 0.050 |
Why?
|
| Cholinergic Agents | 1 | 2021 | 12 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 239 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2021 | 33 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 43 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 91 | 0.050 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 32 | 0.050 |
Why?
|
| Walking | 2 | 2002 | 241 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 2013 | 69 | 0.050 |
Why?
|
| Income | 1 | 2002 | 167 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2021 | 54 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 59 | 0.050 |
Why?
|
| Cattle | 1 | 2002 | 475 | 0.050 |
Why?
|
| Unnecessary Procedures | 1 | 2021 | 49 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 191 | 0.050 |
Why?
|
| Adenoidectomy | 1 | 2021 | 51 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 211 | 0.050 |
Why?
|
| Cytokines | 2 | 2019 | 866 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 82 | 0.050 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 125 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2020 | 251 | 0.040 |
Why?
|
| Self Care | 1 | 2003 | 253 | 0.040 |
Why?
|
| Lebanon | 2 | 2010 | 67 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2016 | 106 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 274 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2019 | 75 | 0.040 |
Why?
|
| ROC Curve | 3 | 2012 | 392 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 36 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 191 | 0.040 |
Why?
|
| Child Development | 1 | 2000 | 102 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 375 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 554 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 384 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Databases as Topic | 1 | 1999 | 49 | 0.040 |
Why?
|
| Eye Diseases | 1 | 2019 | 38 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 145 | 0.040 |
Why?
|
| Rwanda | 1 | 2019 | 3 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2019 | 21 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2011 | 94 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2019 | 20 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 59 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 58 | 0.040 |
Why?
|
| Crohn Disease | 1 | 1999 | 38 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1140 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 8 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 132 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 286 | 0.040 |
Why?
|
| Calibration | 1 | 2019 | 73 | 0.040 |
Why?
|
| Intensive Care Units | 2 | 2013 | 344 | 0.040 |
Why?
|
| Evidence-Based Medicine | 3 | 2007 | 438 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1998 | 6 | 0.040 |
Why?
|
| Serotonin Agents | 1 | 1998 | 13 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2015 | 216 | 0.040 |
Why?
|
| Plaque, Amyloid | 1 | 2018 | 31 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 284 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 948 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 17 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1998 | 13 | 0.040 |
Why?
|
| Patient Care Team | 2 | 2013 | 311 | 0.040 |
Why?
|
| Proteins | 2 | 2013 | 474 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 381 | 0.040 |
Why?
|
| Serotonin | 1 | 1998 | 144 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 193 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2019 | 98 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 62 | 0.040 |
Why?
|
| Registries | 1 | 2001 | 733 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 371 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2018 | 115 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2019 | 122 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2017 | 23 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2019 | 209 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 68 | 0.040 |
Why?
|
| Sodium | 1 | 2018 | 161 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2018 | 136 | 0.040 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2007 | 76 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 383 | 0.040 |
Why?
|
| Remote Sensing Technology | 1 | 2016 | 4 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 315 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2017 | 27 | 0.040 |
Why?
|
| Pyramidal Tracts | 1 | 2017 | 45 | 0.040 |
Why?
|
| Immune Evasion | 1 | 2016 | 19 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2007 | 189 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 61 | 0.030 |
Why?
|
| Stroboscopy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 271 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2018 | 324 | 0.030 |
Why?
|
| Glucose | 2 | 2013 | 307 | 0.030 |
Why?
|
| Laryngoscopy | 1 | 2016 | 61 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2017 | 112 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2017 | 240 | 0.030 |
Why?
|
| Midodrine | 1 | 2015 | 7 | 0.030 |
Why?
|
| Octreotide | 1 | 2015 | 21 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2016 | 78 | 0.030 |
Why?
|
| Ethanol | 1 | 2022 | 893 | 0.030 |
Why?
|
| Exercise Test | 1 | 2016 | 242 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 1996 | 68 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2007 | 235 | 0.030 |
Why?
|
| Inflammation | 2 | 2015 | 1030 | 0.030 |
Why?
|
| Compliance | 1 | 2015 | 26 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 2673 | 0.030 |
Why?
|
| Saliva | 1 | 2016 | 142 | 0.030 |
Why?
|
| Anesthesia | 1 | 2016 | 120 | 0.030 |
Why?
|
| Permeability | 1 | 2015 | 131 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 276 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 60 | 0.030 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2015 | 37 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 103 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 87 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 689 | 0.030 |
Why?
|
| State Government | 1 | 2014 | 34 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 67 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.030 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2014 | 27 | 0.030 |
Why?
|
| Arousal | 1 | 2015 | 168 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 161 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 43 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 631 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 76 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 247 | 0.030 |
Why?
|
| Palliative Care | 2 | 2008 | 271 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 246 | 0.030 |
Why?
|
| Neuronal Apoptosis-Inhibitory Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2006 | 714 | 0.030 |
Why?
|
| Cystitis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Glyburide | 1 | 2013 | 19 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 58 | 0.030 |
Why?
|
| Jaundice, Obstructive | 1 | 2013 | 8 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2014 | 123 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 22 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2013 | 59 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 56 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 157 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 2013 | 66 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2013 | 23 | 0.030 |
Why?
|
| Audiovisual Aids | 1 | 2013 | 20 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2013 | 118 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 129 | 0.030 |
Why?
|
| Manikins | 1 | 2013 | 42 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 186 | 0.030 |
Why?
|
| Professional Practice | 1 | 2013 | 47 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 326 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.030 |
Why?
|
| Health Behavior | 1 | 2017 | 458 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2014 | 109 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 59 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 100 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 86 | 0.030 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2013 | 79 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2013 | 133 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 540 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 248 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 122 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2013 | 156 | 0.030 |
Why?
|
| Health Policy | 1 | 2014 | 221 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 284 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 135 | 0.030 |
Why?
|
| Professional Role | 1 | 2013 | 80 | 0.030 |
Why?
|
| Professional Competence | 1 | 2013 | 100 | 0.030 |
Why?
|
| Plethysmography, Impedance | 1 | 2012 | 17 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2013 | 117 | 0.030 |
Why?
|
| Pressure | 1 | 2013 | 252 | 0.030 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2012 | 22 | 0.030 |
Why?
|
| Caveolin 1 | 1 | 2012 | 59 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2015 | 586 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2012 | 95 | 0.030 |
Why?
|
| Premature Birth | 1 | 2014 | 150 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 126 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1200 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2014 | 284 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 179 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 397 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 129 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 947 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 447 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 150 | 0.020 |
Why?
|
| Career Mobility | 1 | 2011 | 34 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 329 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 111 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2014 | 419 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2012 | 210 | 0.020 |
Why?
|
| Pleurisy | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 250 | 0.020 |
Why?
|
| Dabigatran | 1 | 2011 | 35 | 0.020 |
Why?
|
| Bleomycin | 1 | 2011 | 67 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 274 | 0.020 |
Why?
|
| Paracentesis | 1 | 2011 | 25 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 237 | 0.020 |
Why?
|
| Thrombosis | 1 | 2012 | 218 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 104 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 329 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 597 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2015 | 738 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2013 | 705 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2010 | 38 | 0.020 |
Why?
|
| Antisickling Agents | 1 | 2010 | 20 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 65 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 159 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 204 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2010 | 57 | 0.020 |
Why?
|
| Diuretics | 1 | 2010 | 97 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 138 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Safety Management | 1 | 2010 | 73 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 189 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 202 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2008 | 32 | 0.020 |
Why?
|
| Attitude to Death | 1 | 2008 | 52 | 0.020 |
Why?
|
| Group Practice | 1 | 2008 | 8 | 0.020 |
Why?
|
| Private Practice | 1 | 2008 | 19 | 0.020 |
Why?
|
| Inpatients | 1 | 2010 | 208 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 172 | 0.020 |
Why?
|
| Hemosiderosis | 1 | 2008 | 7 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 39 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 115 | 0.020 |
Why?
|
| Home Care Services | 1 | 2008 | 84 | 0.020 |
Why?
|
| Nursing Records | 1 | 2007 | 10 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 241 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 59 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 72 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2007 | 74 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 82 | 0.020 |
Why?
|
| Drug Costs | 1 | 2008 | 87 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 30 | 0.020 |
Why?
|
| Nurse's Role | 1 | 2007 | 66 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2007 | 113 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 184 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 285 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2009 | 294 | 0.020 |
Why?
|
| Amino Acids | 1 | 2007 | 131 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2008 | 132 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 247 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2007 | 113 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 121 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 140 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 115 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 188 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2007 | 447 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2006 | 219 | 0.020 |
Why?
|
| Physician Assistants | 1 | 2006 | 47 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2005 | 55 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2005 | 69 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 5300 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 432 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 615 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1615 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2005 | 35 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2005 | 147 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2005 | 36 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 1213 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2005 | 79 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 2791 | 0.020 |
Why?
|
| Feedback | 1 | 2004 | 90 | 0.010 |
Why?
|
| Intelligence | 1 | 2003 | 45 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2003 | 96 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2003 | 99 | 0.010 |
Why?
|
| Urban Health | 1 | 2003 | 49 | 0.010 |
Why?
|
| Georgia | 1 | 2003 | 161 | 0.010 |
Why?
|
| Rural Health | 1 | 2003 | 66 | 0.010 |
Why?
|
| Florida | 1 | 2003 | 221 | 0.010 |
Why?
|
| Running | 1 | 2002 | 20 | 0.010 |
Why?
|
| Orthotic Devices | 1 | 2002 | 28 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2002 | 117 | 0.010 |
Why?
|
| Birth Order | 1 | 2000 | 5 | 0.010 |
Why?
|
| Prolactin | 1 | 1998 | 61 | 0.010 |
Why?
|
| Behavioral Symptoms | 1 | 1998 | 32 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1996 | 31 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2000 | 508 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1998 | 517 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 1996 | 107 | 0.010 |
Why?
|